Somaxon Pharma (SOMX) up another 12% premarket, adding to a 27% gain Monday, on speculation...

|About: Somaxon Pharmaceuticals... (SOMX)|By:, SA News Editor

Somaxon Pharma (SOMX) up another 12% premarket, adding to a 27% gain Monday, on speculation ahead of a scheduled FDA action date for its insomnia treatment Silenor. "We continue to view Silenor as having a competitive product profile in a crowded insomnia marketplace, but we remain wary of Somaxon's recent cash balance of $5M and our view of its reliance on Silenor's approval in order to sustain operations, given lack of pipeline depth," S&P said.